Stryker Sells U.S. Spinal Implants Business
Stryker to Sell its U.S. Spinal Implants Business
“We believe that the spinal implants business, with its comprehensive portfolio and strong sales channel, will thrive as an independent company," said Kevin A. Lobo, Chair and Chief Executive Officer, Stryker. "With dedicated resources and a focused strategy, the business will be well positioned to succeed as part of Viscogliosi Brothers.”
Stryker to sell spine business: 8 notes for ASCs
Here are eight things for ASCs to know about the sale: 1. Stryker's U.S. spine segment will be sold to investment firm Viscogliosi Brothers. 2. That group will create VB Spine, which will be a strategic partner to Stryker with exclusive access to the company's Mako Spine and Copilot technology.
Stryker announces definitive agreement for the sale of its U.S. spinal implants business and plans to sell related international business
“We believe that the spinal implants business, with its comprehensive portfolio and strong sales channel, will thrive as an independent company," said Kevin A. Lobo, Chair and Chief Executive Officer, Stryker. "With dedicated resources and a focused strategy, the business will be well positioned to succeed as part of Viscogliosi Brothers.”
Stryker reported goodwill and other impairments of $818 million related to the spine business in the fourth quarter.
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...
Shares of Stryker Corp. SYK slid 1.03% to $391.07 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 0.47% to 6,039.31 and Dow ...
Stryker Corporation's innovation and market leadership justify a premium. See why SYK stock is a solid hold with long-term ...
On Tuesday, Stryker Corp (SYK) stock saw a decline, ending the day at $395.15 which represents a decrease of $-4.75 or -1.19% from the prior close of $399.9. The stock opened at $400.61 and touched a ...
Stryker beat Wall Street estimates for fourth-quarter profit and forecast 2025 earnings largely above expectations on Tuesday, fueled by strong demand for its medical and surgical devices. Medical and ...
In a report released today, Michael Matson from Needham reiterated a Buy rating on Stryker (SYK – Research Report), with a price target of ...
The stock's fall snapped a three-day winning streak.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback